DK3292145T3 - Fc-mutanter med modificeret funktionel aktivitet - Google Patents
Fc-mutanter med modificeret funktionel aktivitet Download PDFInfo
- Publication number
- DK3292145T3 DK3292145T3 DK16726133.8T DK16726133T DK3292145T3 DK 3292145 T3 DK3292145 T3 DK 3292145T3 DK 16726133 T DK16726133 T DK 16726133T DK 3292145 T3 DK3292145 T3 DK 3292145T3
- Authority
- DK
- Denmark
- Prior art keywords
- mutants
- functional activity
- modified functional
- modified
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1554101A FR3035879B1 (fr) | 2015-05-07 | 2015-05-07 | Mutants fc a activite fonctionnelle modifiee |
| PCT/FR2016/051068 WO2016177984A1 (fr) | 2015-05-07 | 2016-05-06 | MUTANTS Fc A ACTIVITÉ FONCTIONNELLE MODIFIÉE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3292145T3 true DK3292145T3 (da) | 2025-03-31 |
Family
ID=54151308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16726133.8T DK3292145T3 (da) | 2015-05-07 | 2016-05-06 | Fc-mutanter med modificeret funktionel aktivitet |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11649271B2 (da) |
| EP (1) | EP3292145B1 (da) |
| JP (1) | JP6830903B2 (da) |
| KR (2) | KR102689154B1 (da) |
| CN (2) | CN107531794B (da) |
| AU (2) | AU2016259124B2 (da) |
| CA (1) | CA2977010A1 (da) |
| DK (1) | DK3292145T3 (da) |
| ES (1) | ES3014454T3 (da) |
| FR (1) | FR3035879B1 (da) |
| MX (1) | MX2017013028A (da) |
| PL (1) | PL3292145T3 (da) |
| WO (1) | WO2016177984A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3035879B1 (fr) | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| EP3497120A1 (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| FR3064007A1 (fr) | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps pour le traitement de cancers |
| FR3075200B1 (fr) * | 2017-12-15 | 2022-12-23 | Lab Francais Du Fractionnement | Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc |
| JP7765181B2 (ja) | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| EP3805400A4 (en) * | 2018-06-04 | 2022-06-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule showing changed half-life in cytoplasm |
| CA3107161A1 (en) * | 2018-08-21 | 2020-02-27 | Bioatla, Inc. | Conditionally active proteins with ph selectivity |
| US20230002450A1 (en) * | 2019-02-18 | 2023-01-05 | Courier Therapeutics, Inc. | Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner |
| JP2023522027A (ja) * | 2020-04-17 | 2023-05-26 | ヤンセン バイオテツク，インコーポレーテツド | 生合成糖タンパク質集団 |
| CN115515975A (zh) * | 2020-05-21 | 2022-12-23 | 兹杜斯生命科学有限公司 | Fc变体及其制备 |
| CN113186167B (zh) * | 2021-04-28 | 2021-11-30 | 中国食品药品检定研究院 | 用于测定抗cd20单克隆抗体药物adcp生物学活性的方法 |
| KR20240003757A (ko) * | 2022-06-29 | 2024-01-09 | 고려대학교 산학협력단 | FcγRIIa 결합 선택성이 향상된 인간 Fc 변이체 |
| US12030945B2 (en) | 2022-10-25 | 2024-07-09 | Seismic Therapeutic, Inc. | Variant IgG Fc polypeptides and uses thereof |
| CN121517545A (zh) * | 2024-08-13 | 2026-02-13 | 菲鹏生物股份有限公司 | 一种Fc突变体及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
| US7355008B2 (en) * | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
| US9200079B2 (en) * | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| MX2012004029A (es) | 2009-10-07 | 2012-05-08 | Macrogenics Inc | Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso. |
| EP3053932B1 (en) * | 2010-02-19 | 2020-07-22 | Xencor, Inc. | Novel ctla4-ig immunoadhesins |
| EP2537864B1 (en) * | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| FR3035879B1 (fr) | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
-
2015
- 2015-05-07 FR FR1554101A patent/FR3035879B1/fr active Active
-
2016
- 2016-05-06 KR KR1020177031051A patent/KR102689154B1/ko active Active
- 2016-05-06 ES ES16726133T patent/ES3014454T3/es active Active
- 2016-05-06 US US15/554,022 patent/US11649271B2/en active Active
- 2016-05-06 WO PCT/FR2016/051068 patent/WO2016177984A1/fr not_active Ceased
- 2016-05-06 CN CN201680025478.7A patent/CN107531794B/zh active Active
- 2016-05-06 EP EP16726133.8A patent/EP3292145B1/fr active Active
- 2016-05-06 MX MX2017013028A patent/MX2017013028A/es unknown
- 2016-05-06 PL PL16726133.8T patent/PL3292145T3/pl unknown
- 2016-05-06 DK DK16726133.8T patent/DK3292145T3/da active
- 2016-05-06 KR KR1020247024678A patent/KR102949160B1/ko active Active
- 2016-05-06 CN CN202210707722.5A patent/CN115073604A/zh active Pending
- 2016-05-06 AU AU2016259124A patent/AU2016259124B2/en active Active
- 2016-05-06 CA CA2977010A patent/CA2977010A1/en active Pending
- 2016-05-06 JP JP2017554315A patent/JP6830903B2/ja active Active
-
2022
- 2022-09-08 AU AU2022228151A patent/AU2022228151B2/en active Active
-
2023
- 2023-03-31 US US18/193,830 patent/US20230265155A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR3035879B1 (fr) | 2025-02-28 |
| AU2022228151B2 (en) | 2025-06-26 |
| KR20240116586A (ko) | 2024-07-29 |
| JP6830903B2 (ja) | 2021-02-17 |
| WO2016177984A1 (fr) | 2016-11-10 |
| FR3035879A1 (fr) | 2016-11-11 |
| BR112017023453A2 (pt) | 2018-07-31 |
| AU2022228151A1 (en) | 2022-09-29 |
| MX2017013028A (es) | 2017-12-08 |
| KR102949160B1 (ko) | 2026-04-06 |
| CN115073604A (zh) | 2022-09-20 |
| EP3292145A1 (fr) | 2018-03-14 |
| CN107531794A (zh) | 2018-01-02 |
| AU2016259124B2 (en) | 2022-06-16 |
| ES3014454T3 (en) | 2025-04-22 |
| EP3292145B1 (fr) | 2025-01-08 |
| KR20180004125A (ko) | 2018-01-10 |
| US20180030111A1 (en) | 2018-02-01 |
| US11649271B2 (en) | 2023-05-16 |
| US20230265155A1 (en) | 2023-08-24 |
| JP2018515446A (ja) | 2018-06-14 |
| CA2977010A1 (en) | 2016-11-10 |
| KR102689154B1 (ko) | 2024-07-29 |
| AU2016259124A1 (en) | 2017-08-31 |
| CN107531794B (zh) | 2022-07-12 |
| PL3292145T3 (pl) | 2025-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250320A0 (en) | Compounds active toward bromodomains | |
| DK3240773T3 (da) | Picolinamidforbindelser med fungicid aktivitet | |
| PL3292145T3 (pl) | Mutanty fc ze zmodyfikowaną aktywnością funkcjonalną | |
| LT3099717T (lt) | Antikūno molekulės tim-3-čiam ir jų panaudojimas | |
| DK3122294T5 (da) | Okklusionsskinneindretning | |
| EP3285644C0 (en) | DETECTION OF ACTIVITY IN PERIPHERAL NERVE | |
| DK3167052T3 (da) | P450-bm3-varianter med forbedret aktivitet | |
| IL259202A (en) | Modified immune cells and uses thereof | |
| DK3105320T3 (da) | Syntetisk nethinde | |
| EP3227160C0 (en) | HARNESS AND PULLING SET | |
| DK3481865T5 (da) | Fc-mutanter med forbedret funktionel aktivitet | |
| DK3201222T3 (da) | Rekombinasemutanter | |
| DK3303243T3 (da) | Spejl med forbedret holdbarhed | |
| DK3430031T3 (da) | Peptider med anti-kræftaktivitet | |
| DK3193936T3 (da) | Antimikrobielle midler med forøget virkning | |
| DK3247496T3 (da) | Udsugningsapparat med reguleret udsugningsindretning | |
| HUE052786T2 (hu) | Diszlipidémia elleni aktivitással rendelkezõ étrendi kompozíció | |
| DK3198099T3 (da) | Møbelhængsel | |
| DK3297292T3 (da) | Ørekop med fastgørelsesenhed | |
| FI10550U1 (fi) | Kylmäkaluste | |
| TH1401001806B (th) | เครื่องขัดผิว | |
| TH1401001808B (th) | เครื่องขัดผิว | |
| BR302014002717S1 (pt) | Configuraçao aplicada em mobiliário | |
| BR302014001370S1 (pt) | Configuração aplicada em mobiliário | |
| BR302014000532S1 (pt) | Configuração aplicada em mobiliário |